Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mass Balance Study of NS-229 in Healthy Adult Males
jRCT2071240076Phase 1Completed
- Sponsor
- Nippon Shinyaku
- Start
- Dec 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of NS-229, sponsored by Nippon Shinyaku. Primary endpoints: Pharmacokinetics of NS-229 and Safety of NS-229. Started Dec 2024; status: completed.
02
Drugs
NS-229
Beyond the preview
Go deeper on jRCT2071240076.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2071240076.